OS Therapies (OSTX) News Today $1.73 -0.09 (-4.95%) Closing price 05/22/2026 04:10 PM EasternExtended Trading$1.74 +0.01 (+0.64%) As of 05/22/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock OSTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period OS Therapies Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comOS Therapies: OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical AdvisorMay 15, 2026 | finanznachrichten.deOS Therapies (OSTX) price target increased by 16.67% to 14.28May 15, 2026 | msn.comOS Therapies (NYSEAMERICAN:OSTX) Downgraded to Strong Sell Rating by Zacks ResearchMay 8, 2026 | marketbeat.comAnalysts Issue Forecasts for OS Therapies Q1 EarningsMay 6, 2026 | marketbeat.comAnalysts Offer Predictions for OS Therapies FY2030 EarningsMay 5, 2026 | marketbeat.comOS Therapies Incorporated (OSTX) Gets a Buy from Lake StreetMay 2, 2026 | theglobeandmail.comOS Therapies Gains EMA Rolling Review for OST-HER2April 30, 2026 | tipranks.comOS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected ...April 30, 2026 | finance.yahoo.comD. Boral Capital Reaffirms Buy Rating for OS Therapies (NYSEAMERICAN:OSTX)April 30, 2026 | marketbeat.comOS Therapies: OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic AdvisorApril 14, 2026 | finanznachrichten.deOS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTXApril 11, 2026 | businesswire.comRosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation - OSTXApril 10, 2026 | tmcnet.comRosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTXApril 10, 2026 | businesswire.comOS Therapies IncorporatedApril 10, 2026 | edition.cnn.comOS Therapies: OS Therapies Appoints Craig Eagle, MD as Strategic AdvisorApril 9, 2026 | finanznachrichten.deOS Therapies bolsters funding to advance OST-HER2 programApril 2, 2026 | tipranks.comOS Therapies Files Prospectus Supplement for Share ResaleMarch 31, 2026 | tipranks.comOS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in ...March 27, 2026 | finance.yahoo.comOS Therapies Raises $2 Million via Convertible NotesMarch 6, 2026 | tipranks.comOS Therapies Extends Warrant Inducement Offering PeriodFebruary 13, 2026 | tipranks.comOS Therapies: OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma ImmunotherapiesFebruary 4, 2026 | finanznachrichten.deLake Street Remains a Buy on OS Therapies Incorporated (OSTX)January 29, 2026 | theglobeandmail.comOS Therapies: OS Therapies Announces Filing Form S-1 of OS Animal Health SubsidiaryJanuary 14, 2026 | finanznachrichten.deOS Therapies Raises Capital Through Warrant Inducement AgreementsJanuary 12, 2026 | tipranks.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)January 5, 2026 | prnewswire.comPromising Outlook for OS Therapies: Buy Rating Backed by Positive FDA Meeting and Strategic PositioningDecember 16, 2025 | tipranks.comOS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of ...December 9, 2025 | finance.yahoo.comD Boral Capital maintains OS Therapies (OSTX) buy recommendationDecember 6, 2025 | msn.comOS Therapies to Spinoff OS Animal Health into Standalone Public CompanyNovember 21, 2025 | finance.yahoo.comLake Street Maintains OS Therapies (OSTX) Buy RecommendationNovember 19, 2025 | msn.comOS Therapies Reports Increased Losses Amid Rising R&D CostsNovember 17, 2025 | tipranks.comOS Therapies falls 5% after reporting wider Q3 loss amid regulatory preparationsNovember 17, 2025 | ca.investing.comOS Therapies shares slip 5% after deeper Q3 loss tied to regulatory pushNovember 17, 2025 | msn.comOS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate ...October 31, 2025 | finanznachrichten.deOS Therapies Releases Investor Presentation for StakeholdersOctober 17, 2025 | tipranks.comOS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary ...October 17, 2025 | finance.yahoo.comPromising Regulatory Progress and Market Potential Justify Buy Rating for OS Therapies’ OST-HER2October 10, 2025 | tipranks.comD. Boral Capital Maintains OS Therapies (OSTX) Buy RecommendationOctober 1, 2025 | msn.comStrategic Regulatory Advances and Promising Clinical Data Drive Buy Rating for OS TherapiesOctober 1, 2025 | tipranks.comOS Therapies Files Prospectus for Stock ResaleSeptember 30, 2025 | tipranks.comOptimistic Buy Rating on OS Therapies Inc. Amid Promising Clinical AdvancementsSeptember 16, 2025 | tipranks.comOS Therapies Raises $3.7M for OST-HER2 LaunchSeptember 2, 2025 | tipranks.comOS Therapies Ends Equity Agreement with Square GateAugust 26, 2025 | tipranks.comOS Therapies Reports Progress in Osteosarcoma TreatmentAugust 25, 2025 | tipranks.comOS Therapies Inc Reports Q2 2025 Earnings: Net Loss Per Share at $0.19, Revenue Details UnavailableAugust 19, 2025 | gurufocus.comEarnings Outlook For OS TherapiesAugust 18, 2025 | benzinga.comOS Therapies Updates Quorum Rules for Shareholder MeetingsAugust 15, 2025 | tipranks.comOS Therapies Delays Q2 2025 Financial ReportAugust 15, 2025 | tipranks.comOS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...August 9, 2025 | finance.yahoo.com Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OSTX Media Mentions By Week OSTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OSTX News Sentiment▼0.130.45▲Average Medical News Sentiment OSTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OSTX Articles This Week▼22▲OSTX Articles Average Week Get the Latest News and Ratings for OSTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for OS Therapies and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Eledon Pharmaceuticals News Today Anavex Life Sciences News Today ALX Oncology News Today Compugen News Today Akebia Therapeutics News Today Protara Therapeutics News Today Prelude Therapeutics News Today Zentalis Pharmaceuticals News Today Editas Medicine News Today Alector News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:OSTX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
